Plenty of excitement has been generated recently in the immuno-oncology sphere by the accelerated [Food & Drug Administration] approvals in May 2016 for Bristol-Myers Squibb Co.’s PD-1 antagonist, Opdivo (nivolumab), in relapsed/refractory classical Hodgkin’s lymphoma and for Genentech Inc.’s PD-L1 antagonist, Tecentriq (atezolizumab), in relapsed/refractory, advanced or metastatic urothelial carcinoma. Those approvals, along with an abundance of data reported at the ASCO 2016 annual meeting on immuno-oncology (a query of the ASCO 2016 annual meeting abstracts using the keywords related to immune-oncology resulted in almost 1500 abstracts), seems to have spurred multiple investment deals in June and already in July, according to Strategic Transactions.
But which immuno-oncology candidates are poised to begin their first-in-human (FIH) clinical trials? How many sponsors already have partners or...







